LitAlert ~~

    • BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees.
    • Cortesi L, Domati F, Guida A, Marchi I, Toss A, Barbieri E, Marcheselli L, Venturelli M, Piana S, Cirilli C, Federico M.
    • Cancer Biol Med. 2021 Mar 12:j.issn.2095-3941.2020.0481. doi: 10.20892/j.issn.2095-3941.2020.0481. Epub ahead of print.
    • Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.
    • Li MZ, Meng T, Song SS, Bao XB, Ma LP, Zhang N, Yu T, Zhang YL, Xiong B, Shen JK, Miao ZH, He JX.
    • Invest New Drugs. 2021 Mar 12. doi: 10.1007/s10637-021-01096-4. Epub ahead of print.
    • Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    • de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, Garcia EBG, Ausems MGEM, Collée JM, van Engelen K, van de Beek I; HEBON group, Smit VTHBM, Rookus MA, de Bock GH, van Leeuwen FE, Bosse T, Dekkers OM, van Asperen CJ.
    • J Natl Cancer Inst. 2021 Mar 12:djab036. doi: 10.1093/jnci/djab036. Epub ahead of print.


    BRCA1/2 and Endometrial Cancer Risk: Implications for Management.

    • An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
    • Cortesi L, Rugo HS, Jackisch C.
    • Target Oncol. 2021 Mar 12. doi: 10.1007/s11523-021-00796-4. Epub ahead of print.
    • Coinheritance of germline mutations in APC and BRCA1 in colorectal cancer: A case report.
    • Wei Huang, Jin Bian, Xiaoping Qian, Lin Shao, Haiyan Li, Lu Zhang and Lin Wang
    • Front Oncol. 2021 Mar 10;10:658389. doi: 10.3389/fonc.2021.658389.
    • A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
    • Huang L, Lang GT, Liu Q, Shi JX, Shao ZM, Cao AY.
    • Ann Transl Med. 2021 Feb;9(4):301. doi: 10.21037/atm-20-4852.